BAX · Baxter International

The thesis

Baxter International's shares are more likely to lag the S&P 500 over the next three months: sales growth has recovered, but margins fell in the third quarter and management named 2027 cost headwinds. The fourth-quarter 2026 report, due in February 2027 with the first 2027 guidance, settles whether earnings follow sales.

The shares closed at $26.34 on 11 November 2026. That is 12.2% below the 52-week high of $30.00 reached on 30 July 2026 and above both the 50-day average ($24.54) and the 200-day average ($21.57). The market has already paid for the recovery and the guidance raise. The three post-report analyst targets found sit below the close: JPMorgan $25, Wells Fargo $25 and Barclays $23.

Baxter reported third-quarter sales of $2.976 billion on 29 October 2026, up 5% reported and organic. Adjusted diluted earnings per share (EPS) were $0.58 against a $0.52 estimate in company-news coverage. Adjusted EPS fell 16% year over year, which the company attributed to a higher tax rate of 18.3%.

Baxter also issued an announcement on 4 November 2026 headlined "Baxter International Updates Full-Year 2026 Guidance and Reports Debt Reduction". The guidance figures in this note are those in the 29 October 2026 results release.

Bullish and bearish views on Baxter International Inc.

The bull case on Baxter International Inc. (BAX), in brief: sales growth held at 5%. The bear case: margins narrowed while sales grew.

Bull case

• Sales growth held at 5%. Third-quarter sales rose 5% reported and organic on 29 October 2026. Medical Products & Therapies grew 6% to about $2.1 billion and Healthcare Systems & Technologies grew 4% to $806 million.
• The earnings floor moved up. Baxter raised 2026 adjusted diluted EPS guidance to $2.05–$2.15 from $1.95–$2.15, and organic sales growth guidance to 3%–4% from 2%–3%. The $0.58 quarterly result beat the $0.52 estimate cited in company-news coverage.
• Debt is coming down. A $600 million cash tender offer retired $864 million of debt in the third quarter, with a pretax gain of about $253 million excluded from adjusted results. Management reiterated on the 29 October 2026 call a target of about 3 times net leverage by year-end 2026. Guided non-operating expense is $245–$255 million.
• Cash flow was large. Free cash flow was $448 million in the third quarter and $705 million year to date. Management said the quarter was helped by a legal settlement and a tariff refund received late.

Bear case

• Margins narrowed while sales grew. Adjusted gross margin was 38.3% against 39.4% a year earlier, and adjusted operating margin was 14.5%, down 0.4 percentage point. Adjusted operating income rose 2% to $432 million on 5% sales growth. Investing.com headlined its review of the Q3 slides "strong results overshadowed by margin concerns".
• 2027 carries named headwinds. On the 29 October 2026 call management said the one-time tariff refund in 2026 will not recur, inflation steps up in 2027, and Vantive transition services end around January 2027. The cephalosporin antibiotic exit removes about $50 million of sales and $30 million of operating income. Management called the net effect a headwind without sizing it.
• Injectables and plant quality remain weak. Injectables sales fell 3% in the third quarter on price deflation and manufacturing problems at the Round Lake plant. An FDA warning letter followed an earlier-2026 inspection there, and management gave no resolution date. The FDA classified a Duo-Vent solution set removal as Class I on 13 August 2026.
• Analyst targets sit below the price. On 30 October 2026 JPMorgan kept a Neutral rating and lowered its target to $25, and Wells Fargo kept Equal-Weight and raised its target to $25. On 9 November 2026 Barclays kept an Underweight rating and raised its target to $23. All three are below the 11 November 2026 close of $26.34.

Price setup

The shares closed at $26.34 on 11 November 2026, after closes of $25.79 on 6 November 2026 and $26.50 on 4 November 2026. The 50-day average is $24.54 and the 200-day average is $21.57, so the shares trade above both. The 3-month change is −2.6%, against a close of $27.05 on 13 August 2026.

The 52-week high is $30.00 (intraday, 30 July 2026). The 52-week closing low is $15.80 on 30 March 2026, so the shares have recovered well above that low even though they remain below the July high.

No earnings date falls inside the next 30 days. SEC Form 4 filings show only share withholding for taxes by executives on 1 September 2026 and 2 September 2026, including 54,276 shares withheld from chief executive Andrew Hider at $25.70. No open-market insider sales are listed since then.

Catalysts ahead

• ~31 December 2026 (est.): Baxter's year-end target of about 3 times net leverage. Shows whether the debt paydown that supports lower interest cost and the 2026 earnings range is on schedule.
• 11 January 2027: JPMorgan Healthcare Conference (runs to 13 January 2027). A scheduled forum where management can comment on 2027 margins, the Vantive services roll-off and the Round Lake plant.
• February 2027 (est.): Fourth-quarter 2026 report with first 2027 guidance. Settles whether earnings follow sales once the tariff refund, Vantive services and cephalosporin sales drop out.

What would change the view

A daily close above $29.24, 11% above the 11 November 2026 close of $26.34, which would show the shares leading the S&P 500. A February 2027 outlook for adjusted EPS above the $2.15 top of the 2026 range would also show the shares leading.

What it trades with

Baxter trades as a single company with its own case, driven by hospital IV demand, pricing contracts, tariffs and its debt load. Interest cost matters more than for most hospital-product peers because of the debt paydown. Moves in hospital-supply and medical-device shares still affect the price, but Baxter's own margin trend and plant-quality news are the larger drivers of the shares. Tariff policy is a shared exposure with other US medical-supply companies, and Baxter's 2026 results include a one-time tariff refund.